CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 6885323
• 负责人: CLIFFORD A HUDIS
• 金额: $ 18.39万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-30 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6885323
• 关键词: aging; antineoplastics; breast neoplasms; cancer prevention; cancer registry /resource; cis platinum compound; clinical research; clinical trial phase I; clinical trial phase II; clinical trial phase III; combination cancer therapy; combination chemotherapy; cooperative study; doxorubicin; drug resistance; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human subject; human therapy evaluation; irinotecan; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; oncology nursing; paclitaxel; pathology; patient oriented research; prostate neoplasms; psychological aspect of cancer; quality of life; respiratory neoplasm; tamoxifen; thorax neoplasm; urinary tract neoplasms

Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's clinical research programs are tightly allied with those of the Cancer and Leukemia Group B (CALGB). Physician-scientists at MSKCC maintain leadership positions in the CALGB across a variety of disease-specific areas and treatment modalities and have significant administrative responsibilities for the group. Research programs at MSKCC are designed to optimally utilize the large patient population and extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific and clinical research programs at MSKCC are developed with the intention of ultimately testing them, when appropriate, in the larger patient populations afforded by our participation in the CALGB. During the next six years, under recently recruited leadership, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs. The enclosed grant will provide resources for continued participation in the CALGB and for increased contributions by MSKCC to the group's success.

纪念斯隆-凯特琳癌症中心（MSKCC）是一个独立的机构，致力于通过住院和门诊护理，临床和研究培训计划以及广泛的研究活动来控制癌症。MSKCC的临床研究项目与癌症和白血病组B（CALGB）的临床研究项目紧密相关。MSKCC的医生科学家在CALGB的各种疾病特定领域和治疗模式中保持领导地位，并对该集团承担重大行政责任。MSKCC的研究项目旨在最佳利用大量患者人群和临床和实验室研究人员的广泛，多学科工作人员，并鼓励在基础科学中应用发现，以促进预防，检测，诊断和治疗多种形式的癌症。MSKCC的科学和临床研究项目是为了最终在适当的时候在我们参与CALGB所提供的更大患者人群中进行测试而开发的。在接下来的六年里，在最近招募的领导下，MSKCC将继续扩大其临床和研究设施以及研究和培训计划。所附赠款将为继续参与CALGB和MSKCC对该集团的成功作出更多贡献提供资源。